Skip to main content


Log in

Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript



To report the clinical, ultrasound and histopathological characteristics, clinical management, and prognosis of 13 patients with Sertoli-Leydig cell tumors (SLCTs) of ovary.


13 patients with pathologically confirmed ovarian SLCTs at International Peace Maternity and Child Health Hospital from 2010 and 2019 were included in this study. The clinical, ultrasound and histopathological characteristics, clinical management, and prognosis of 13 patients were retrospectively analyzed.


The age ranged 25–68 years. Of the 8 (62%) patients presenting endocrine symptoms, 4 had post-menopausal hemorrhage, 4 had menstrual irregularity, 2 had androgenic manifestations, 1 had hirsutism, and 1 showed acne with thyroid nodules. 1 patient had elevated cancer antigen 125 (CA125), and 2 had elevated testosterone (T). The other 5 patients showed no symptoms of whom masses were detected incidentally by physical examination. All tumors were at stage I and confined to unilateral ovary. 11 tumors were solid or mixed solid-cystic masses with clear boundaries on ultrasound, and 1 tumor was a cystic mass. 7 tumors were intermediately differentiated and 6 were poorly differentiated, among which 1 case had heterologous elements (poorly differentiated) and 8 had a retiform pattern. Grade 2 endometrial cancer occurred in 2 cases (1 intermediately differentiated and 1 poorly differentiated). One case had multinodular goiter (intermediately differentiated). The patients were classified into endocrine function group (8/13) and no endocrine function (5/13). The proportion of retiform pattern of the group with endocrine function was significantly higher than that of no endocrine function group (p < 0.05). However, the mean age, diameter of tumors, and the proportions of poor differentiation and rupture showed no significant difference. All patients were treated with surgical excision. Three cases underwent surgery twice after the pathological results came out. For the final surgery, 1 patient underwent cystectomy, 3 underwent unilateral salpingo-oophorectomy, and 9 underwent total hysterectomy and bilateral salpingo-oophorectomy. 7 had received postoperative chemotherapy. All of 13 patients exhibited disease-free survival (DFS) with the longest follow-up time being 9 years.


The clinical characteristics and imaging findings may provide information for the diagnosis of SLCTs. Higher percentage of retiform pattern was found in endocrine function group. Concurrence of Grade 2 endometrial carcinoma with SCLTs was reported. The prognosis of SLCTs is good. Conservative surgery is acceptable for young patients wishing to preserve fertility.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Lantzsch T, Stoerer S, Lawrenz K, Buchmann J, Strauss HG, Koelbl H (2001) Sertoli-Leydig cell tumor. Arch Gynecol Obstet 264(4):206–208

    Article  CAS  PubMed  Google Scholar 

  2. Young RH, Scully RE (1985) Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 9(8):543–569.

    Article  CAS  PubMed  Google Scholar 

  3. Schneider DT, Orbach D, Cecchetto G, Stachowicz-Stencel T, Brummel B, Brecht IB, Bisogno G, Ferrari A, Reguerre Y, Godzinski J, Bien E, Calaminus G, Göbel U, Patte C (2015) Ovarian Sertoli-Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT). Eur J Cancer 51(4):543–550.

    Article  PubMed  Google Scholar 

  4. Akman L, Ertas IE, Gokcu M, Terek MC, Sanci M, Sanli UA, Zekioglu O, Ozsaran AA (2016) Ovarian Sertoli-Leydig cell tumors: a multicenter long-term clinicopathological analysis of 27 patients. J Cancer Res Ther 12(1):290–294.

    Article  CAS  PubMed  Google Scholar 

  5. Gui T, Cao D, Shen K, Yang J, Zhang Y, Yu Q, Wan X, Xiang Y, Xiao Y, Guo L (2012) A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors. Gynecol Oncol 127(2):384–389.

    Article  PubMed  Google Scholar 

  6. Gouy S, Arfi A, Maulard A, Pautier P, Bentivegna E, Leary A, Chargari C, Genestie C, Morice P (2019) Results from a monocentric long-term analysis of 23 patients with Ovarian Sertoli-Leydig cell tumors. Oncologist 24(5):702–709.

    Article  CAS  PubMed  Google Scholar 

  7. Sigismondi C, Gadducci A, Lorusso D, Candiani M, Breda E, Raspagliesi F, Cormio G, Marinaccio M, Mangili G (2012) Ovarian Sertoli-Leydig cell tumors: a retrospective MITO study. Gynecol Oncol 125(3):673–676.

    Article  PubMed  Google Scholar 

  8. Zhang X, Shen D, Wang Y (2018) Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors. Pathol Res Pract 214(9):1370–1375.

    Article  CAS  PubMed  Google Scholar 

  9. Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L (2008) Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 31(1):85–91.

    Article  CAS  PubMed  Google Scholar 

  10. Colombo N, Peiretti M, Garbi A, Carinelli S, Marini C, Sessa C (2012) Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(7):vii20–vii26

    Article  PubMed  Google Scholar 

  11. Kawatra V, Mandal S, Khurana N, Aggarwal SK (2009) Retiform pattern of Sertoli-Leydig cell tumor of the ovary in a 4-year-old girl. J Obstet Gynaecol Res 35(1):176–179.

    Article  PubMed  Google Scholar 

  12. Mooney EE, Nogales FF, Bergeron C, Tavassoli FA (2002) Retiform Sertoli-Leydig cell tumours: clinical, morphological and immunohistochemical findings. Histopathology 41(2):110–117.

    Article  CAS  PubMed  Google Scholar 

  13. Xu Q, Zou Y, Zhang XF (2018) Sertoli-Leydig cell tumors of ovary: a case series. Medicine 97(42):e12865.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Zhang H-Y, Zhu J-E, Huang W, Zhu J (2014) Clinicopathologic features of ovarian Sertoli-Leydig cell tumors. Int J Clin Exp Pathol 7(10):6956–6964

    PubMed  PubMed Central  Google Scholar 

  15. Soleimanpour H, Shirian S, Oryan A, Daneshbod K, Bagheri N, Daneshbod Y (2011) Cytologic, immunocytologic, histopathologic and immunohistologic diagnosis of the poorly differentiated sertoli-leydig cell tumor. Acta Cytol 55(4):382–386.

    Article  CAS  PubMed  Google Scholar 

  16. Nam SM, Kim JW, Eoh KJ, Kim HM, Lee JY, Nam EJ, Kim S, Kim SW, Kim YT (2017) A novel clinicopathological analysis of early stage ovarian Sertoli-Leydig cell tumors at a single institution. Obstet Gynecol Sci 60(1):39–45.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Zaloudek C, Norris HJ (1984) Sertoli-Leydig tumors of the ovary. A clinicopathologic study of 64 intermediate and poorly differentiated neoplasms. Am J Surg Pathol 8(6):405–418

    Article  CAS  PubMed  Google Scholar 

  18. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, de Geest K, Gershenson DM (2014) Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: results of a phase 2 trial of the Gynecologic Oncology Group. Cancer 120(3):344–351.

    Article  CAS  PubMed  Google Scholar 

  19. Brown J, Shvartsman HS, Deavers MT, Burke TW, Munsell MF, Gershenson DM (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22(17):3517–3523

    Article  CAS  PubMed  Google Scholar 

  20. Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, Rotmensch J, Tate Thigpen J, Van Le L (2016) A phase II study of paclitaxel for the treatment of ovarian stromal tumors: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 140(1):48–52.

    Article  CAS  PubMed  Google Scholar 

  21. Haley M, Bindal P, McAuliffe A, Vredenburgh J (2019) A family with Sertoli-Leydig cell tumour, multinodular goiter, and mutation. Curr Oncol (Toronto, Ont) 26(3):183–185.

    Article  CAS  Google Scholar 

  22. de Kock L, Terzic T, McCluggage WG, Stewart CJR, Shaw P, Foulkes WD, Clarke BA (2017) DICER1 mutations are consistently present in moderately and poorly differentiated Sertoli-Leydig cell tumors. Am J Surg Pathol 41(9):1178–1187.

    Article  PubMed  Google Scholar 

  23. Schultz KAP, Harris AK, Finch M, Dehner LP, Brown JB, Gershenson DM, Young RH, Field A, Yu W, Turner J, Cost NG, Schneider DT, Stewart DR, Frazier AL, Messinger Y, Hill DA (2017) DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry. Gynecol Oncol 147(3):521–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Schultz KA, Harris A, Messinger Y, Sencer S, Baldinger S, Dehner LP, Hill DA (2016) Ovarian tumors related to intronic mutations in DICER1: a report from the international ovarian and testicular stromal tumor registry. Fam Cancer 15(1):105–110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Clement PB, Gilks CB, Huntsman DG, Kommoss F (2019) DICER1 and FOXL2 mutation status correlates with clinicopathologic features in Ovarian Sertoli-Leydig cell tumors. Am J Surg Pathol 43(5):628–638.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations



YG: data collection, data analysis, and manuscript writing; JW: data collection; YHL and YDW: manuscript writing and manuscript editing.

Corresponding authors

Correspondence to Yuhong Li or Yudong Wang.

Ethics declarations

Conflict of interest

We declare that we do not have any conflict of interest.

Ethical approval

All the procedures performed in studies involving human participants were in accordance with the ethical standards of Ethics Committee of International Peace Maternity and Child Health Hospital in Shanghai and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The publication of this case report has the permission of the patient.

Human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Informed consent was obtained from all individual participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guo, Y., Wang, J., Li, Y. et al. Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases. Arch Gynecol Obstet 302, 203–208 (2020).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: